Abstract 522P
Background
The standard treatment of relapsed small cell lung cancer (SCLC) has not been established yet, and weekly paclitaxel (PTX) is recommend as one of the treatment options for relapsed SCLC. In advanced non-small cell lung cancer, nanoparticle albumin-bound paclitaxel (nab-PTX) has shown equal activity to PTX with less neurological adverse event. However, the benefit of nab-PTX for relapsed SCLC has not been fully evaluated yet. The aim of this study is to evaluate efficacy and safety of both weekly nab-PTX and weekly PTX regimen for relapsed SCLC.
Methods
We retrospectively reviewed consecutive relapsed SCLC patients who were treated with weekly nab-PTX (80mg/m2, day1,8,15/q4 weeks) or weekly PTX (80mg/m2, day1,8,15,22/q4 weeks) at Tosei general hospital, from January 2008 to March 2019. We evaluated the objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse event profile in each regimen.
Results
A total of 52 patients with relapsed SCLC were reviewed, 18 and 34 patients received weekly nab-PTX (group A) and weekly PTX (group B), respectively. Patient characteristics (group A: group B) were as follows; male 17 (94%): 28(82%), median of age 74 :70, ECOG-PS 0-1 18(100%) :29(85%), extensive disease 14(78%) :17(50%), refractory relapse 16(89%) :20(59%). ORR in group A and B were 5.6% and 8.8%, and DCR in group A and B were 55.6% and 38%, respectively. The PFS and OS had no difference between group A and B (median PFS, 3.2months and 1.7months; median OS, 5.4 months and 4.5months). Toxicity profile of group A was tolerable as well as group B. About neurological adverse event, group A had less toxicity than group B in any grade (5(28%) and 12(35%) patients) but no severe adverse event was observed.
Conclusions
Weekly nab-PTX and weekly PTX showed similar efficacy for relapsed SCLC. In terms of toxicity, weekly nab-PTX might be less toxic especially in neurological adverse event. Although this is a retrospective single center study, the nab-PTX might be a treatment option for relapsed SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hajime Oi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract